Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the UK / NCT07054684
Recruiting Phase 1

Study of BHV-1400 in IgA Nephropathy

NCT07054684 · tracked via the Priya Life Science UK tracker
Sponsor
Biohaven Therapeutics Ltd
Phase
Phase 1
Started
2025-07-30
Last updated
2026-06-23

Condition(s) studied

IgA Nephropathy

Investigational drug(s) / intervention(s)

BHV-1400

BHV-1400: BHV-1400 is delivered subcutaneously (SC)

Study summary

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Primary outcome measure(s)

  • Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deaths — Up to 1 year
    To assess the safety and tolerability of BHV-1400. This objective will be measured by assessing the number of unique subjects with SAEs, moderate or severe AEs, AEs leading to discontinuation or deaths
  • Number of participants with Grade 3-4 treatment-emergent laboratory abnormalities — Up to 1 year
    To assess the safety and tolerability of BHV-1400. This objective will be measured by assessing the number of unique subjects with Grade 3 or 4 treatment-emergent laboratory abnormalities.

Trial sites (15)

FacilityCityRegionStatus
Site-001 Farmington Connecticut Recruiting
Site-003 Miami Lakes Florida Recruiting
Site-011 Miami Lakes Florida Recruiting
Site-013 Orlando Florida Recruiting
Site-005 Pembroke Pines Florida Recruiting
Site-008 Lawrenceville Georgia Recruiting
Site-009 Hinsdale Illinois Recruiting
Site-012 Indianapolis Indiana Recruiting
Site-015 Shelby Michigan Recruiting
Site-006 Chesterfield Missouri Recruiting
Site-002 Dakota Dunes South Dakota Recruiting
Site-014 Houston Texas Recruiting
Site-004 Houston Texas Recruiting
Site-016 Salt Lake City Utah Recruiting
Site-007 Leicester United Kingdom Recruiting

More Biohaven Therapeutics Ltd. trials in the UK

Long-term Safety and Tolerability of BHV-7000 Enrolling by invitation
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Active, not recruiting

Other trials for the same condition

Phase 2b Open-Label Repeat Kidney Biopsy Study Active, not recruiting
Atrasentan in Patients With Proteinuric Glomerular Diseases Active, not recruiting
Atrasentan in Patients With IgA Nephropathy Active, not recruiting
A Study of Zigakibart in Adults With IgA Nephropathy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07054684 on ClinicalTrials.gov ↗ ← All trials in the UK